Musely Secures $360M Equity-Free Mega-Round

The rules of late-stage startup financing are being rewritten. **Musely**, the health-tech pioneer known for its telemedicine-driven prescription skincare platform, has announced a landmark **$360 million** funding round led by **General Catalyst**. However, unlike a traditional Series D, this round is entirely **equity-free**, allowing the founders to maintain full control of the company while securing the capital needed for global expansion.

The "Revenue-Based Mega-Round"

The deal utilizes a sophisticated "Customer Value" financing model. Instead of trading shares for cash, Musely is effectively selling a percentage of its future predictable revenue streams to General Catalyst over a fixed term. This "non-dilutive" approach has historically been limited to smaller, sub-$10M rounds for SaaS startups. Musely’s ability to secure nearly $400M under these terms is a testament to its massive, loyal customer base and the high margins of its direct-to-consumer prescription model. General Catalyst has described the deal as a "conviction play on the sustainability of profitable deeptech."

Founder Control in the AI Era

The push for equity-free financing is driven by a desire among elite founders to remain independent in an era of rapid AI disruption. By avoiding the "growth at all costs" mandate that often accompanies traditional VC equity, Musely's leadership can prioritize long-term R&D—such as its upcoming **AI-driven diagnostic engine**—without pressure from a board to hit quarterly exit milestones. This trend is being closely watched by AI infrastructure startups, who are increasingly looking for ways to fund their massive compute requirements without diluting their ownership of core model weights.

The Shift in Venture Capital

For firms like General Catalyst, these deals represent a transition from "gambling on exits" to "investing in yield." As the IPO market remains volatile in 2026, VCs are seeking more predictable ways to return capital to their limited partners. "We are moving toward a 'Hybrid Capital' model," stated a General Catalyst partner. "For companies with proven unit economics and clear cash flow, equity is often the most expensive way to raise money. We want to provide the alternative."

As Musely prepares to use this capital to launch its personalized medicine platform in Europe and Asia, the "equity-free mega-round" is likely to become the new blueprint for late-stage category leaders who value sovereignty as much as scale.